



ReNetX Bio Adds Financial Expertise to its Board of Directors, Appointing Sean Cassidy, MBA

New Haven, Conn., Jan. 13, 2021 -- ReNetX Bio, Inc., a privately held, clinical-stage company committed to reversing disease and damage for patients suffering from central nervous system (CNS) disorders, announces the addition of Sean Cassidy, MBA, to its Board of Directors.

Mr. Cassidy is the Chief Financial Officer of Arvinas (NASDAQ: ARVN) where he negotiated and closed multiple license and collaboration agreements with leading pharmaceutical companies including Merck, Genentech, a subsidiary of Roche, Pfizer, and Bayer Pharmaceuticals. In addition, Sean assisted in establishing a joint venture with Bayer Crop Sciences pursuing Arvinas's targeted protein degradation technology in agriculture applications called Oerth Bio and sits on the Oerth Bio's board. Cassidy also led Arvinas's initial public offering of common stock in 2018. During Sean's nearly 20 years of experience in the life science industry he has held various executive positions at multiple successful biotech companies including at CuraGen and 454 Life Sciences. Cassidy has been committed to ReNetX Bio's goal of addressing neurological injury and diseases and served as CFO early in the company's development.

"We're thrilled to welcome Sean to our Board of Directors at this important stage of ReNetX Bio's evolution," said Erika Smith, CEO of ReNetX Bio. "As a highly respected and seasoned finance executive, we look forward to Sean's expert engagement in guiding our financing and partnering strategy in the next exciting phase of our growth."

"This is an exciting time at the company as it progresses its lead candidate into later stage clinical trials and the unmet medical need for patients with chronic spinal cord injury is so great," Cassidy says. "I look forward to working alongside my fellow Board members and company management to advance truly innovative therapies to benefit patients."

The lead drug candidate from ReNetX, AXER-204, is a first-in-class therapy designed to remove inhibitory proteins from the CNS environment allowing for axonal regrowth and increased plasticity. These changes harness the body's ability to regenerate new neural connections through rewiring. The company has a strong development pipeline and is currently in Phase 1/2 clinical trials.

About ReNetX Bio, Inc.: For more information, please visit www.renetx.com